Oxolamine

Oxolamine (SKF-9976) is an orally active antitussive. Oxolamine can inhibit CYP2B1/2. Oxolamine has anti-inflammatory effects on the respiratory organs of guinea pigs. Oxolamine increases the AUC of Warfarin (HY-B0687) and prolongs its terminal half-life. Oxolamine can be used in respiratory disease research^[1][2][3][4]. In Vitro:Oxolamine (SKF-9976 citrate) 是一种具有口服活性止咳剂。Oxolamine 可以抑制 CYP2B1/2。Oxolamine 对豚鼠呼吸器官具有抗炎作用。Oxolamine 增加 Warfarin (HY-B0687) 的 AUC 并延长其终末半衰期。Oxolamine 可用于呼吸道疾病研究^[1][2][3][4]。 In Vivo:Oxolamine (10-50 mg/kg; p.o.; 3 times per day for 3 consecutive days) significantly increases the AUC and prolongs the terminal half-life of Warfarin (HY-B0687) in male SD rats^[3].
Oxolamine (80 mg/kg body weight initially, then 53.3 mg/kg; i.p.; 11 times at 3, 6, 9, 24, 28, 32, 48, 52, 56, 72 and 76 h) shows a distinct anti-inflammatory action on the respiratory organs of guinea pigs^[4].